# Ipamorelin: bones, weight and recovery

> Ipamorelin: bones and weight | High Peak Peptides — High Peak Peptides follows ipamorelin through rat bone growth, ferret weight loss, a brief human hormone pulse and an inconclusive bowel-recovery trial.

Longer bones in rats and less weight lost by ferrets make an unusual pair of findings. They are also a useful antidote to a single story about getting leaner.

## Ipamorelin bone measurements

In [adult female rats, ipamorelin increased longitudinal bone growth](https://pubmed.ncbi.nlm.nih.gov/10373343/). The measured rates were 42 micrometres/day with vehicle and 44, 50 and 52 micrometres/day across the experimental treatment groups. Total IGF-1, IGF-binding proteins and the measured bone-turnover markers did not change.

The awkwardness of this result delights me. Growth appeared in the bone measurement while the familiar circulating growth protein stayed unchanged. It makes a compact account of ipamorelin as simply “more GH, therefore more IGF-1” look incomplete.

These are rat bone-growth findings. They establish neither increased adult human height nor improved human fracture recovery. The biological question is interesting enough to survive that limit.

## Less weight lost by ferrets

A [2024 ferret experiment studied chemotherapy-associated weight loss](https://pubmed.ncbi.nlm.nih.gov/39043357/). Ipamorelin reduced the later weight loss by approximately 24%. It did not reduce the vomiting induced by cisplatin in that experiment.

Here, retaining weight was the desirable direction. A smaller body, to my mind, makes a poor universal ambition, although much discussion of these compounds assumes that goal. The experimental purpose came from the condition being modelled.

The ferrets’ result concerns chemotherapy-associated weight loss in ferrets. It provides no established benefit for people receiving chemotherapy and no evidence for human fat loss.

![Sable ferret standing beside a ceramic bowl in an observation enclosure](images/ferret-observation.webp)

*Generated gouache scene of a ferret in an observation enclosure. It accompanies animal research on chemotherapy-associated weight loss and depicts neither an actual study animal nor a treatment outcome.*

## Human ipamorelin findings

Ipamorelin acts at the ghrelin receptor, a different receptor from the GHRH target used by sermorelin and CJC-1295. In [healthy male volunteers receiving intravenous ipamorelin](https://pubmed.ncbi.nlm.nih.gov/10496658/), the GH response peaked at about 40 minutes and the compound’s terminal half-life was approximately 2 hours.

The later [published Phase 2 bowel-resection trial enrolled 114 adults](https://pubmed.ncbi.nlm.nih.gov/25331030/). Median time to the first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo, with p=0.15. The primary endpoint was missed. Treatment-emergent adverse events occurred in 87.5% and 94.8% of the respective groups; these totals include events around surgery and cannot all be assigned to treatment.

I’d hoped the human outcome would be more decisive after the animal findings. The trial leaves the proposed recovery benefit unestablished. Intravenous human data also leave other routes of use uncharacterised by those experiments.

## Reports and cardiovascular caution

Sleep, vivid dreams, recovery and changes in body shape appear in anecdotal accounts, not clinical evidence establishing those benefits. Accounts also mention flushing, hunger, puffiness, tingling, dizziness and fatigue. Some describe fading effects. There is no reliable clinical timetable in those reports.

A [related ghrelin-receptor agonist caused myocardial degeneration in rats](https://pubmed.ncbi.nlm.nih.gov/25722321/). Ipamorelin was not the compound tested. The result raises a class-level cardiovascular question while leaving ipamorelin’s own long-term cardiovascular effects uncertain.

Ipamorelin has never gained approval for human treatment. Short human studies leave blood-sugar effects, fluid retention and long-term safety unsettled. The potential for GH/IGF-1 to promote cell growth is a mechanistic cancer concern, rather than a cancer finding from an ipamorelin trial. The unusual animal results reward my curiosity; the [human comparison](/compare) shows how much work remains before they can carry adult health claims.

---

An independent field notebook for the GH axis—where every peak keeps its time stamp, every claim keeps its source, and no curve becomes medical advice.